flavin-mononucleotide and Stroke

To evaluate the efficacy of including cytoflavin in rehabilitation measures in the early recovery period of patients with ischemic stroke.. Results of rehabilitation measures of 100 patients (50 women and 50 men, aged 18 to 85 years) in the early recovery period of ischemic stroke were analyzed. Psychological testing included NIHSS, MMSE, Rankin scale, Rivermead mobility index, exercise tolerance test. Depending on the rehabilitation scheme, patients were divided into the main group (n=50), who received a verticalization course and cytoflavin (intravenously, drip 20.0 ml in 250.0 ml 5% glucose for 14 days). The control group (n=50) included patients who received standard treatment.. Inclusion of cytoflavin in the rehabilitation scheme for patients with ischemic stroke increased the effectiveness of treatment, which was manifested by a decrease in the severity of neurological disorders assessed with NIHSS by 17.6% in the main group versus 10.8% in the control group (p<0.05) and recovery of cognitive functions assessed with MMSE by 5.8% versus 1.6%, respectively (p<0.05). In addition, there was a positive dynamics in the restoration of blood pressure (by 37.1% in the main group versus 30.6% in the control group (p<0.05)).. Цель исследования. Оценка эффективности включения препарата Цитофлавин в схемы реабилитационных мероприятий пациентов в раннем восстановительном периоде ишемического инсульта. Материал и методы. Проанализированы результаты реабилитационных мероприятий у 100 пациентов (50 женщин и 50 мужчин в возрасте от 18 до 85 лет) в раннем восстановительном периоде ишемического инсульта. Неврологическое и психологическое обследования включали следующие методики: шкалы NIHSS, MMSE и Рэнкина, индекс мобильности Ривермид и тест на толерантность к физическим нагрузкам. В зависимости от схемы реабилитации пациенты были разделены на две группы. В основную группу вошли 50 пациентов, получивших курс вертикализации и Цитофлавин: внутривенно, капельно 20,0 мл в 250,0 мл 5% глюкозы в течение 14 сут. Группу сравнения составили 50 больных, получивших стандартный курс реабилитации. Результаты и заключение. Включение Цитофлавина в схему реабилитации пациентов с ишемическим инсультом повысило эффективность лечения, что проявилось уменьшением выраженности неврологических нарушений (по шкале NIHSS) на 17,6% в основной группе против 10,8% в группе сравнения (р<0,05) и восстановлением когнитивных функций (по шкале ММSE) на 5,8% против 1,6% соответственно (р<0,05). Кроме того, была отмечена положительная динамика восстановления артериального давления - на 37,1% в основной группе против 30,6% в группе сравнения (р<0,05).

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Cognition; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Stroke; Stroke Rehabilitation; Succinates; Treatment Outcome; Young Adult

To analyze the effect of cytoflavin on neurological functions, the level of independence in daily living tasks, psychoemotional condition and quality of life in poststroke patients.. We have analyzed the results of treatment of 1450 stroke patients. Half of the patients received cytoflavin, and the other was treated without this drug. The functional rehabilitation was followed up using Barthel, Lindmark, Scandinavian and Merton and Sutton scales, psychoemotional condition was assessed with the Beck Depression Questionnaire and the Wakefield Depression Scale, quality of life - with the Sickness Impact Profile.. Cytoflavin improved the recovery of neurological functions and social adaptation, normalized the psychoemotional condition and increased quality of life of poststroke patients.

Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Emotions; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Prospective Studies; Social Adjustment; Stroke; Stroke Rehabilitation; Succinates

In the multicenter randomized clinical-instrumental prospective study 185 patients aged 55-75 years (mean age 68 years) with 94 men and 91 women with cerebral infarction were included. All the patients were hospitalized in the period from 6 to 24 hours from the time of the debut of clinical symptoms, 42,2% of patients scored 14 and above on NIH scale on admission. Patients were randomized into 3 groups: 1st group consisted of 64 patients treated as an antioxidant by 5% solution of ascorbic acid 2 times a day the recommended dose (20 ml/day) for 20 days; 2nd group consisted of 72 patients who received energy monitor Cytoflavin in a daily dose of 20 ml (10.0 ml/drip 2 times a day for 10 days); 3rd group consisted of 49 patients with Cytoflavin therapy extended to 20 days, moreover from 11th to 20th day the dose was 10 ml/day. Cytoflavin treatment was more efficient than ascorbic acid, which can be explained by different pharmacologic mechanisms. Treatment with Cytoflavin for 10 days resulted in a significant decrease of ischemia zone volume by 25% in average, treatment with Cytoflavin for 20 days--by 29%, which manifested in better outcomes in neurologic and functional status. Ascorbic acid demonstrated no effect on morphologic parameters. Patients having at the time of admission 18-20 points according to the NIH and treated with Cytoflavin for 20 days demonstrated significant trend towards improvement of the parameters of the neurological status.

Topics: Aged; Aged, 80 and over; Antioxidants; Ascorbic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Energy Metabolism; Female; Flavin Mononucleotide; Homeostasis; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Prospective Studies; Severity of Illness Index; Stroke; Succinates; Treatment Outcome

Sixty patients were randomized to treatment with cytoflavin (n=30) or nootropil (n=30). Patients of the main group received cytoflavin along with standard treatment for correction of hemodynamics. The treatment scheme was as follows: intravenous injections during 10 days, tablets - from 11 to 35 days. The same scheme of treatment was used in the comparison group. The total duration was 35 days. Patients were assessed with NIHSS, the Rankin scale, the Barthel index, MMSE. MRI was used to verify ischemic lesions. The therapeutic efficacy of cytoflavin was significantly higher compared to nootropil in respect to the restoration of neurological functions and self-service abilities as well as to the reduction of cognitive deficit.

Topics: Administration, Intravenous; Aged; Antioxidants; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Neuroprotective Agents; Niacinamide; Piracetam; Stroke; Succinates; Treatment Outcome

We present the results of a multicenter study on efficacy of cytoflavin in the treatment of patients with acute ischemic stroke. Seventy patients (41 of the main group and 29 of the control group) were enrolled in the study. All patients received basic therapy aimed at improving systemic hemodynamics, rheological blood properties and at the prevention of stroke complications. Patients of the main group were treated with cytoflavin as follows: days 1-10 - 20 ml (in 400 ml of the 0,9% NaCl solution) twice a day intravenously in drops; days 11-35 - 850 mg twice a day. We assessed the dynamics of restoration of lost functions (NIHSS, the Rankin scale, the Barthel index) and volumes of ischemic lesion (MRI T1-, T2-, diffusion-weighted images). Results of the study on patients of the control group were supplemented with literature data about 306 patients studied using clinical scales and 40 patients studied with MRI. We revealed a trend towards an effect of cytoflavin on the preservation of brain matter in the acute phase of stroke. Cytoflavin reduced the neurological deficit and improved activities of daily living in patients that may be explained by the less brain damage.

Topics: Aged; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Recovery of Function; Severity of Illness Index; Stroke; Succinates; Treatment Outcome

To assess an effect of cytoflavin on the results of rehabilitation treatment and the increase in exercise tolerance in patients with stroke complicated by post-intensive care syndrome (PICS).. The data of 53 patients who underwent neurorehabilitation in the ICU after ischemic stroke were analyzed. Depending on the treatment regimen, the patients were divided into two groups. Group 1 (main,. The components of the energytropic effect of cytoflavin can have a positive modulating effect, increasing the tolerance of rehabilitation measures for the treatment of PICS in patients with ischemic stroke. Further research is required.. Оценка влияния Цитофлавина на результаты реабилитационного лечения и повышение толерантности к физической нагрузке у пациентов с инсультом, осложненным синдромом после интенсивной терапии (ПИТ).. Проанализированы данные 53 пациентов, прошедших нейрореабилитацию в условиях отделения реанимации и интенсивной терапии после ишемического инсульта. В зависимости от схемы лечения больные были разделены на 2 группы: основную (

Topics: Brain Ischemia; Critical Care; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Niacinamide; Stroke; Stroke Rehabilitation; Succinates; Treatment Outcome

To explore the endogenous and pharmacological activation of neurotrophic mechanisms in a model of brain ischemic lesion in rats.. The study was performed on 170 male albino rats (195-205 g). The model of ischemic stroke was accomplished by the electrocoagulation of the proximal segment of the left middle cerebral artery and simultaneous permanent ligation of the left common carotid artery.. The evaluation of NSE, NO, VEGF, NGF levels in the brain cytoplasmic lysate and plasma showed the delayed activation of neurotrophic mechanisms in astrocytes accompanied by a decrease in delayed alteration of neurons. The use of cytoflavin in the treatment of stroke was accompanied by the earlier and more intense activation of neurotrophic mechanisms in astrocytes, delayed activation of neurotrophic mechanisms in endothelial cells, which promoted neuroprotection in acute ischemic stroke.. Цель исследования - изучение особенностей эндогенной и фармакологической активации нейротрофических механизмов при моделировании острого ишемического повреждения головного мозга у крыс. Материал и методы. Исследование было выполнено на 170 самцах-альбиносах серых крыс. Ишемический мозговой инсульт моделировали путем электрокоагуляции проксимального сегмента левой средней мозговой артерии с одновременным наложением постоянной лигатуры на левую общую сонную артерию. Результаты и заключение. Оценка содержания NSE, NO, VEGF, NGF в цитолизате головного мозга и плазме крови выявила отсроченную активацию нейротрофических механизмов в астроцитах, сопровождающуюся уменьшением отсроченного повреждения нейронов. Применение цитофлавина в лечении инсульта в эксперименте сопровождалось более ранней и более интенсивной активацией нейротрофических механизмов в астроцитах, отсроченной активацией нейротрофических механизмов в эндотелиоцитах, что позволяло на более ранних сроках обеспечить нейропротекцию при развитии ишемического инсульта.

Topics: Animals; Astrocytes; Disease Models, Animal; Drug Combinations; Flavin Mononucleotide; Inosine Diphosphate; Male; Nerve Growth Factors; Neurons; Neuroprotective Agents; Niacinamide; Nitric Oxide; Phosphopyruvate Hydratase; Rats; Stroke; Succinates; Vascular Endothelial Growth Factor A

To study an influence of cytoflavin on normalization of cognitive functions, psychoemotional condition and a quality of life in stroke patients.. It was analysed the results of treatment of 1450 stroke patients. The cognitive functions was followed up using MMSE and MoCA scales, psychoemotional condition--Beck Depression Questionnaire and Wakefield Depression Scale, Hamilton Scale of Anxiety, quality of life--Sickness Impact Profile.. The results of the study revealed that the use of cytoflavin was well founded in the treatment of stroke patients for improvement of cognitive functions, psychoemotional condition and the quality of life.. Цель исследования - изучение влияния нейроцитопротективной терапии с использованием препарата цитофлавин на уровень социально-бытовой адаптации, психоэмоциональный статус, состояние когнитивных функций и качество жизни пациентов, перенесших инсульт. Материал и методы. В исследование были включены 1450 пациентов, перенесших инфаркт головного мозга, которые составили две группы по 725 человек (получавшие и не получавшие цитофлавин), сопоставимые по возрасту, полу, степени выраженности неврологических и психоэмоциональных нарушений, уровню бытовой адаптации, качеству жизни, а также проводимым видам и методам реабилитации (принцип matched-controlled). Проводилась оценка когнитивных функций с помощью краткой шкалы оценки психического статуса - MMSE и Монреальской шкалы оценки когнитивных функций (МоСА), психоэмоционального состояния с помощью опросника Бека, шкалы самооценки депрессии Уэйкфилда, шкалы тревоги Гамильтона, качества жизни с помощью профиля влияния болезни (Sickness Impact Profile). Результаты и заключение. Результаты исследования показали, что применение цитофлавина статистически достоверно способствует нормализации когнитивных функций, психоэмоционального состояния пациентов после инсульта, а также приводит к улучшению качества их жизни.

Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Psychiatric Status Rating Scales; Quality of Life; Stroke; Succinates; Surveys and Questionnaires; Treatment Outcome

We studied the clinical efficacy of cytoflavin in 30 patients (group 1) with I and II stages of discirculatory encephalopathy (DE) and a depressive syndrome associated with arterial hypertension. Cytoflavin was added to standard treatment intravenously in drops in dose 10 ml per 200 ml of 0,9% NaCl during 10 days and then in dose 2 tablets twice a day during 25 days. The control group (n=29 patients) received placebo. The treatment duration was 35 days but patients were followed up for 90 days with control visits at 5, 10, 20-35 and 65-90 days of treatment. After the treatment, there was the reduction of neurological symptoms and subjective disorders in patients of group 1. The improvement of attention concentration, reasoning and speech activity as well as the gradual restoration of memory were noted at 20-35 days. The positive impact of cytoflavin on depression was dependent on its severity. The effect was higher in mild depression, also, the treatment decreased the severity of depression from "moderate" or "severe' to "mild". Cytoflavin may be recommended for patients with DE and a depressive syndrome associated with arterial hypertension as a preventive medication from the progression of cerebrovascular pathology and development of stroke.

Topics: Cerebrovascular Disorders; Depressive Disorder; Drug Combinations; Female; Flavin Mononucleotide; Humans; Hypertension; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Psychiatric Status Rating Scales; Stroke; Succinates; Treatment Outcome

A study of free radical processes (FRP) markers in 381 patients with ischemic and hemorrhagic stroke revealed the importance of oxidant stress that was most severe in patients with large volumes of stroke. Intensification of FRP consists in the reduction or inversion of oxygen FRP activity and increase in lipid free radical FRP that last till the patient discharge from a hospital. FRP indicators are early prognostic markers of stroke course and outcome. An inverse correlation between the level of anti peroxide plasma activity (APA) and the dynamics of the increase in stroke lesion from 1 to 20 days, and direct correlation between malondialdehyde (MDA) titer and the risk of hemorrhagic transformation and growth of the lesion from 5 to 20 days of disease were revealed. The results indicate that inclusion of antoixidant therapy should be conducted as early as possible after stroke using high doses of drugs in severe cases. The high efficacy of antioxidant cytoflavin in a daily dose of 20 ml in patients with stroke of different character and severity was shown. The positive effect of cytoflavin on FRP markers was accompanied by the improvement of clinical and morphological presentations and stroke outcome.

Topics: Aged; Antioxidants; Biomarkers; Brain Ischemia; Drug Combinations; Female; Flavin Mononucleotide; Free Radicals; Humans; Inosine Diphosphate; Intracranial Hemorrhages; Magnetic Resonance Imaging; Male; Malondialdehyde; Middle Aged; Niacinamide; Prognosis; Stroke; Succinates

Based on complex clinical-biochemical studies of 60 patients after ischemic stroke (on average 2,4+/-0,3 years from the disease-onset), we showed the disturbance of balance between anti- and prooxidant systems. The changes in the parameters of oxidative stress were revealed as follows: the reduction in the activity of antioxidant defense markers (superoxiddismutase, catalase, oxidized and reduced glutathione), as well as in the spontaneous and induced hemoluminescence, the increase of malonic dialdehyde, a final product of lipid peroxidation. The changes in biochemical parameters were correlated with the severity of ischemic stroke consequences, assessed by the Rankin scale and the Barthel index. This finding points out the necessity of including antioxidants in the rehabilitation treatment. The effect of antioxidant drugs on the consequences of ischemic stroke was studied using cytoflavin (10 ml in 200 ml of 5% glucose solution daily intravenous in drops during 10 days) and cortexin (10 mg in 2 ml of 5% novocaine solution daily intramuscular during 10 days). The results revealed a higher effect of cytoflavin that was supported by the data of clinical-biochemical blood analysis: the level of components of glutathione system and catalase was significantly (p<0,05) increased in patients with sensory-motor disturbances and cognitive disorders thought did not reach the levels of control group.

Topics: Aged; Antioxidants; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Niacinamide; Peptides; Stroke; Succinates; Treatment Outcome